

## **CSF Lactate In Cryptococcal Meningitis**

### **Cerebrospinal Fluid Lactate as a Prognostic Marker of Disease Severity and Mortality in Cryptococcal Meningitis**

Mahsa Abassi<sup>1,2</sup>, Ananta S Bangdiwala<sup>2</sup>, Edwin Nuwagira<sup>3</sup>, Kiiiza Kandole Tadeo<sup>1</sup>, Michael Okirwoth<sup>1</sup>, Darlisha A Williams<sup>1,2</sup>, Edward Mpoza<sup>1</sup>, Lillian Tugume<sup>1</sup>, Kenneth Ssebambulidde<sup>1</sup>, Kathy Huppler Hullsiek<sup>2</sup>, Abdu K Musubire<sup>1,4</sup>, Conrad Muzoora<sup>3</sup>, Joshua Rhein<sup>1,2</sup>, David B Meya<sup>1,2,4</sup>, David R Boulware<sup>2</sup>, and ASTRO-CM team

#### **Affiliations:**

1 Infectious Diseases Institute, Kampala, Uganda,

2 University of Minnesota, Minneapolis, Minnesota,

3 Mbarara University of Science and Technology,

4 School of Medicine, College of Health Sciences, Makerere University

**Corresponding Author:** Mahsa Abassi DO, University of Minnesota, 689 23<sup>rd</sup> Ave SE, Minneapolis, MN 55455-3007 USA. Email: [abass004@umn.edu](mailto:abass004@umn.edu)

**Keywords:** Cryptococcal Meningitis, Cerebrospinal Fluid, Lactic Acid, Prognostic Marker, Mortality

**Summary:** In HIV-associated cryptococcal meningitis, baseline cerebrospinal fluid (CSF) lactate levels are associated with increased intracranial pressures, seizures, and altered mental status. Elevated CSF lactate levels, at baseline, are associated with increased 2-week mortality.

**Word Count: Abstract: 248/250 Text: 2359**

## CSF Lactate In Cryptococcal Meningitis

### Abstract:

**Background:** Cerebrospinal fluid (CSF) lactate levels can differentiate between bacterial and viral meningitis. We measured CSF lactate in individuals with cryptococcal meningitis to determine its clinical significance.

**Methods:** We measured point-of-care CSF lactate at the bedside of 319 HIV-infected Ugandan adults at diagnosis of cryptococcal meningitis. We summarized demographic variables and clinical characteristics by CSF lactate tertiles. We evaluated the association of CSF lactate with clinical characteristics and survival.

**Results:** Individuals with high CSF lactate  $>5$  mmol/L at cryptococcal diagnosis more likely presented with altered mental status ( $p<.0001$ ), seizures ( $p=.0005$ ), elevated intracranial opening pressure ( $p=.03$ ), higher CSF white cells ( $p=0.007$ ), and lower CSF glucose ( $p=.0003$ ) compared to those with mid-range (3.1 to 5 mmol/L) or low ( $\leq 3$  mmol/L) CSF lactate levels. Two-week mortality was higher among individuals with high baseline CSF lactate  $>5$  mmol/L (35%; 38/109) as compared to individuals with mid-range (22%; 25/112) or low CSF lactate (9%; 9/97;  $p<.0001$ ). After multivariate adjustment, CSF lactate  $>5$ mmol/L remained independently associated with excess mortality (adjusted Hazard Ratio = 3.41; 95%CI, 1.55-7.51;  $p=.002$ ). We found no correlation between baseline CSF lactate levels and blood capillary lactate levels ( $p=.72$ ).

**Conclusions:** Baseline point-of-care CSF lactate levels may be utilized as a prognostic marker of disease severity and mortality in cryptococcal meningitis. Individuals with an elevated baseline CSF lactate are more likely to present with altered mental status, seizures, elevated CSF opening

## CSF Lactate In Cryptococcal Meningitis

pressures, and are at a greater risk of death. Future studies are needed to determine targeted therapeutic management strategy in persons with high CSF lactate.

### **Introduction:**

The measurement of CSF lactate has been shown to have utility in the rapid differentiation of bacterial meningitis from viral meningitis.[1, 2] In cases of acute meningitis, CSF lactate concentrations of >4.2 mmol/L have a sensitivity of 96% in the presumptive diagnosis of bacterial meningitis.[1] However, despite the high sensitivity, CSF lactate measurements are highly nonspecific and are also found to be elevated in several other infectious and noninfectious neurological conditions, including cerebral malaria, tuberculous meningitis, cryptococcal meningitis, cerebral injury, subarachnoid hemorrhage, seizures, and ischemia.[3-7] As a diagnostic tool, the current recommended clinical application to use CSF lactate, as dictated by the Infectious Diseases Society of America guidelines, is in the diagnostic work up of bacterial meningitis after postoperative neurological procedures.[5, 8]

As a prognostic marker in cases of bacterial meningitis, individuals with higher CSF lactate levels demonstrate a trend towards lower Glasgow coma score and higher mortality.[1, 2] In cases of bacterial meningitis, serial measurements of CSF lactate predict future clinical outcomes. Specifically, a greater than 50% decline in CSF lactate measurements in the first 3 days of treatment resulted in an improved clinical course.[1] A similar trend has been reported in cerebral malaria and in cases of severe head injury, where the normalization of CSF lactate has favorable clinical outcomes, while persistently elevated or increasing CSF lactate levels result in overall poor clinical outcomes including severe disability or death.[3, 5]

## CSF Lactate In Cryptococcal Meningitis

In sub-Saharan Africa, HIV-associated cryptococcal meningitis is the most common cause of meningitis, accounting for 15% of AIDS-related deaths globally.[9-11] In low-income countries where the burden of cryptococcal meningitis is greatest, 2-week mortality ranges between 17% and 28% in clinical trials, with one-year mortality as high as 70% in routine care. [9] In HIV-associated cryptococcal meningitis, CSF lactate levels have been found to be elevated (median 3.0 mmol/L (IQR 2.7 to 5.8)) at the time of diagnosis.[4] However, the significance of elevated CSF lactate levels in cryptococcal meningitis is not well understood. We sought to understand the prognostic significance of elevated baseline CSF lactate levels in HIV-associated cryptococcal meningitis.

### Methods:

#### *Study design and participants:*

The study included Ugandan adults presenting with first-episode cryptococcal meningitis at Kiruddu General Hospital in Kampala and Mbarara Regional Referral Hospital from September 2016 to March 2020. Persons diagnosed with cryptococcal meningitis were enrolled into the Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis (ASTRO-CM) clinical trial (ClinicalTrials.gov identifier: NCT01802385) through May 2017. After conclusion of ASTRO-CM, participants were enrolled in an observational cohort focused on meningitis diagnostics.[12-14] All participants enrolled into the studies provided written informed consent. Participants were treated with standard antifungal therapy and those who were enrolled into ASTRO-CM were randomized to either receive adjunctive sertraline (400 mg/day for 14 days, followed by 200 mg/day for 12 weeks) or placebo. Standard antifungal therapy was amphotericin B (0.7-1.0 mg/kg/day) for up to 14 days and fluconazole 800 mg/day for ~4 weeks,

## CSF Lactate In Cryptococcal Meningitis

followed by fluconazole 400 mg/day for 8 weeks of consolidation therapy, and fluconazole 200 mg/day for secondary prophylaxis. Participants in the randomized trial were followed up for 18 weeks, while participants in the observational study were followed for 2 weeks or until hospital discharge.

### *Lactate Measurements:*

All participants had a baseline lumbar puncture performed at the time of cryptococcal meningitis diagnosis. CSF lactate measurements were performed bedside at the time of lumbar puncture (Lactate Plus Analyzer; Sports Resource Group Inc., Hawthorne, NY). In addition to CSF lactate measurements, a subset of individuals also had matched serum lactate measurements performed concurrently at baseline.

### *Statistical Methods:*

CSF lactate measurements were grouped into tertiles. We summarized baseline demographic variables and clinical characteristics by CSF lactate tertiles, presented as percentages and medians with interquartile range. We evaluated the relationship between CSF lactate level and 2-week mortality using log-rank tests and visually summarized by Kaplan-Meier curves. We used Cox proportional hazards models to estimate hazard ratios by CSF lactate level, adjusted for Glasgow coma score <15, baseline seizures, quantitative *Cryptococcus* CSF culture, and CSF opening pressure.

We conducted an area under the receiver operating characteristic (ROC) curve analysis of the continuous  $\log_2$  transformed CSF lactate as a predictor of 2-week mortality to consider a threshold cut point of lactate risk for mortality. As sensitivity analyses, we used Cox proportional hazards models to consider lactate cut at the threshold from the AUC result, and as a continuous

## CSF Lactate In Cryptococcal Meningitis

variable. We compared clinical characteristics of individuals who died as compared to those who survived at 2-weeks using Cox proportional hazards model. We used the Spearman correlation to estimate the correlation between CSF lactate and serum lactate. We performed analyses using SAS version 9.4 (SAS Institute, Cary, North Carolina).

### Results:

Of 622 participants with a first episode of cryptococcal meningitis, 51% (319/622) had a CSF lactate measurement performed at baseline. Demographic and clinical characteristics of participants with a CSF lactate measurement are summarized by CSF lactate tertiles in **Table 1**. CSF lactate measurements (overall median 3.9, IQR [2.8, 5.7], range [1.1, 12.0]) were grouped into low ( $\leq 3$  mmol/L; n=97), mid-range (3.1 – 5.0 mmol/L, n=113), and high ( $>5.0$ , n=109) tertiles with distribution displayed in **Figure 1**.

Among persons diagnosed with HIV-associated cryptococcal meningitis, we found several demographic and clinical factors to be associated with elevated CSF lactate levels. Participants with high CSF lactate,  $>5.0$  mmol/L, had significantly higher baseline CSF white cells ( $p=.007$ ) and lower CSF glucose ( $p=.0003$ ) than participants with low or mid-range CSF lactate measurements at baseline. There were no differences in CSF quantitative *Cryptococcus* culture ( $p=.25$ ) or CSF protein ( $p=.25$ ) between lactate tertiles. However, participants with high baseline CSF lactate also had higher intracranial opening pressures (median 27 cm H<sub>2</sub>O IQR, 17 to 40) than participants with mid-range (median 23 cm H<sub>2</sub>O IQR, 16 to 33) or low baseline CSF lactate levels (median 22 cm H<sub>2</sub>O IQR, 14 to 30) ( $p=.03$ ). A significantly greater percentage of participants with high baseline CSF lactate presented with a Glasgow coma score  $<15$  (71%) as compared to mid-range CSF lactate (39%) or participants with low (30%) ( $p<.0001$ ). Baseline

## CSF Lactate In Cryptococcal Meningitis

seizures were also more frequent in participants presenting with high baseline CSF lactate at the time cryptococcal meningitis diagnosis (high: 30% vs. mid-range: 16% and low: 9%;  $p=.0006$ ).

Two-week mortality was significantly higher among individuals with high baseline CSF lactate compared to individuals with mid-range and low CSF lactate levels (high: 35% (38/109) vs. mid-range: 22% (25/112) and low: 9% (9/97);  $p<.0001$ ) (**Figure 2**). In multivariate analysis, after adjusting for Glasgow coma score, baseline seizure, baseline opening pressures, and quantitative *Cryptococcus* CSF culture, individuals with high baseline CSF lactate continued to be at a three-fold higher risk of mortality at 2-weeks compared to those with CSF lactate  $\leq 3.0$  mmol/L (adjusted Hazard Ratio = 3.41; 95% CI, 1.55 to 7.51;  $p=.0021$ ) (**Table 2**). The increased risk of mortality with higher lactate levels was also seen in sensitivity analysis when considering baseline CSF lactate as continuous variable (aHR=1.13 for each 1 mmol/L increase in baseline CSF lactate, 95% CI, 1.02 to 1.24) (**Table 2**). An area under a receiver-operator characteristic curve analysis found a CSF lactate cut-off point of 4.3 mmol/L as having the highest sensitivity and specificity for predicting 2-week mortality (AUC: 0.664; 95%CI, 0.60 to 0.73). In sensitivity analysis, those with baseline CSF lactate of 4.3 mmol/L or greater had a two-fold higher risk of mortality at 2 weeks compared to those with baseline CSF lactate  $< 4.3$  mmol/L (aHR 2.10, 95% CI, 1.22 to 3.62) (**Table 2**).

We assessed for other possible confounders for association with 2-week mortality, in those who presented with CSF lactate  $>5.0$  mmol/L. There was a notable difference in the percentage of people with baseline Glasgow coma score  $<15$  in those who died as compared to those who survived (died: 78% (29/38) vs. survived: 59% (42/71);  $p=.05$ ). Among persons who died at 2-weeks, baseline hemoglobin was higher in those who survived (died: median 10.2 g/dL; IQR, 8.1 to 12.6 vs. survived: median 11.6 g/dL; IQR, 9.7 to 13.1;  $p=.04$ ). There was also a

## CSF Lactate In Cryptococcal Meningitis

difference in baseline serum creatinine levels, such that people who died at 2-weeks presented with higher baseline serum creatinine compared to those who survived, ( $p=.001$ ). There were no significant differences in baseline CSF opening pressures ( $p=.22$ ), CSF glucose ( $p=.36$ ), or quantitative *Cryptococcus* CSF culture ( $p=.24$ ) in persons who survived compared to those who died at 2-weeks.

Among persons with CSF lactate measurements at baseline, 37 individuals had matched capillary blood lactate also measured. No correlation existed between CSF and capillary blood lactate levels ( $r^2=0.02$ ;  $p=.60$ ) (**Figure 3**). Whole blood lactate levels did not differ between low, mid-range, and high CSF lactate tertiles ( $p=.72$ ).

### Discussion:

In this study, we demonstrate that a high baseline CSF lactate level is a reliable prognostic marker of disease severity in HIV-associated cryptococcal meningitis. Persons with HIV-associated cryptococcal meningitis who have elevated CSF lactate levels  $>5.0$  mmol/L are also more likely to present with altered mental status (Glasgow coma score  $<15$ ) and seizures at diagnosis. An elevated CSF lactate level  $>5.0$  mmol/L is also accompanied by elevated intracranial pressures, higher CSF white cells, and lower CSF glucose. In contrast, CSF lactate levels are not associated with the burden of *Cryptococcus* based on a lack of association with quantitative CSF cultures. Persons with a baseline CSF lactate level  $>5.0$  mmol/L were at a 3-fold increased risk of death at 2-weeks compared to those with levels  $\leq 3.0$  mmol/L. Even after controlling for Glasgow coma score, opening pressure, and CSF quantitative *Cryptococcus* cultures, high CSF lactate ( $>5.0$  mmol/L) was found to be an independent predictor for increased 2-week mortality. Assessing for clinical risk factors among persons with a CSF lactate of  $>5.0$

## CSF Lactate In Cryptococcal Meningitis

mmol/L who died versus those who survived at 2-weeks, persons who died were more likely to also present with a lower hemoglobin value and higher creatinine levels at baseline.

While CSF lactate levels widely varied in cryptococcal meningitis, we did not find a correlation between CSF and capillary blood lactate measurements. Though lactate crosses the blood brain barrier through monocarboxylic acid transporters, the lack of correlation between CSF and capillary lactate levels may suggest a centrally occurring disease process, which is not systemic. Thereby suggesting that the increased mortality observed in persons with HIV-associated cryptococcal meningitis presenting with high baseline CSF lactate is a CNS driven process, which therefore requires compartment-specific interventions.

The exact mechanism behind CSF lactate elevations in cryptococcal meningitis and its association with mortality is unclear. We postulate that, in HIV-associated cryptococcal meningitis, decreases in cerebral perfusion and cerebral hypoxia leads to the clinical presentation of altered mental status, seizures, and increased intracranial pressures at the time of presentation. The observed CSF profile, increase in white cell count, low glucose, and high lactate would support an inflammatory CNS process that may be a result of or contributing to decreasing cerebral perfusion and cerebral hypoxia. Furthermore, when comparing 2-week survival among persons with cryptococcal meningitis who presented with a baseline CSF lactate  $>5.0$  mmol/L, individuals who died had lower baseline hemoglobin levels. Our results would support the assumption that mortality may be driven by decreased cerebral perfusion and possibly cerebral ischemia.

In cryptococcal meningitis, percent regional cerebral tissue oxygenation ( $rSO_2$ ), as measured by cerebral oximetry, has been shown to be a predictor of 2-week mortality.[15] Such

## CSF Lactate In Cryptococcal Meningitis

that individuals with low cerebral perfusion are >3 times more likely to die within 30-days.

Similar to CSF lactate, cerebral oximetry is independently associated with mortality after having controlled for altered mental status, CSF quantitative *Cryptococcus* culture, CSF white cell count, and anemia. Low hemoglobin levels decrease oxygen carrying capacity and are strongly correlated with measured rSO<sub>2</sub> and mortality. In fact, in previous cryptococcal meningitis cohorts, low hemoglobin levels have repeatedly been shown to be associated with increased mortality.[16-18]

While CSF glucose has long been recognized as highly variable in cryptococcal meningitis, the significance of glucose and other metabolic derangements has not been well characterized. The high-energy demand of the brain creates a state of dependence on aerobic metabolism and a continuously sufficient supply of oxygen and glucose for cellular metabolism. A lack of adequate cerebral perfusion, by either a reduction in the oxygen carrying capacity or cerebral ischemia secondary to increased intracranial pressures or seizures may explain the rise in CSF lactate. The oxidation of pyruvate and gluconeogenesis require the presence of oxygen. When oxygen levels fall, glucose is primarily converted to lactate. Thus, decreased cerebral perfusion leading to an increased risk for mortality would be supported by our observation of low CSF glucose levels in the presence of elevated CSF lactate.

High CSF lactate is independently associated with mortality, after controlling for increased intracranial pressures, altered mental status, and CSF quantitative *Cryptococcus* culture. This raises the possibility of irreversible CNS damage. In neurocritical care settings, cerebral microdialysis measurements of the lactate and pyruvate ratio help to distinguish between insufficient tissue oxygenation, which may be reversible and mitochondrial damage, which may lead to neural cell death.[19] Further research to assess changes in metabolite levels, in addition

## **CSF Lactate In Cryptococcal Meningitis**

to lactate and pyruvate, in cryptococcal meningitis will be critical to understanding the degree of neurocellular damage in order to design targeted interventions to reduce mortality. Optimizing cerebral perfusion and oxygen delivery to the brain may be important aspects of the supportive management of neuroinfections.

While our study is the largest thus far in evaluating CSF lactate levels in cryptococcal meningitis, we were limited in our ability to longitudinally evaluate the effects of CSF lactate on outcomes. We were also limited by our sample size to focus on risk factors in individuals with high baseline CSF lactates  $>5.0$  mmol/L. Despite these limitations, we believe that our study has important clinical implications in the management of cryptococcal meningitis.

In conclusion, results of our study demonstrate that in cryptococcal meningitis, baseline CSF lactate levels may be used as a prognostic marker for disease severity and as a clinical tool to risk stratify individuals who are at an increased risk of death. Our findings suggest that in individuals with cryptococcal meningitis, baseline CSF lactate levels  $>5.0$  mmol/L should be used to identify those at increased risk of early, 2-week mortality to target further interventions. Further research needs to be done to better understand the underlying pathophysiology of elevated CSF lactate levels in cryptococcal meningitis.

## **CSF Lactate In Cryptococcal Meningitis**

**Funding:** This work was supported by the U.S. Fogarty International Center (K01TW010268, R25TW009345); National Institute of Neurologic Diseases and Stroke (R01NS086312); National Institute of Allergy and Infectious Diseases (T32AI055433); and the United Kingdom Medical Research Council / Wellcome Trust/ Department for International Development (MRC MR/M007413/1). DBM was also supported by DELTAS Africa Initiative (grant number DEL-15-011) to THRiVE-2. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences Alliance for Accelerating Excellence in Science in Africa and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (grant number 107742/Z/15/Z) and the UK Government.

**Conflicts of Interest:** No conflicts of interest

## CSF Lactate In Cryptococcal Meningitis

### References:

1. Genton B, Berger JP. Cerebrospinal fluid lactate in 78 cases of adult meningitis. *Intensive Care Med* **1990**; 16(3): 196-200.
2. Giulieri S, Chapuis-Taillard C, Jatou K, et al. CSF lactate for accurate diagnosis of community-acquired bacterial meningitis. *Eur J Clin Microbiol Infect Dis* **2015**; 34(10): 2049-55.
3. White NJ, Warrell DA, Looareesuwan S, Chanthavanich P, Phillips RE, Pongpaew P. Pathophysiological and prognostic significance of cerebrospinal-fluid lactate in cerebral malaria. *Lancet* **1985**; 1(8432): 776-8.
4. de Almeida SM, Boritza K, Cogo LL, et al. Quantification of cerebrospinal fluid lactic acid in the differential diagnosis between HIV chronic meningitis and opportunistic meningitis. *Clin Chem Lab Med* **2011**; 49(5): 891-6.
5. DeSalles AA, Kontos HA, Becker DP, et al. Prognostic significance of ventricular CSF lactic acidosis in severe head injury. *J Neurosurg* **1986**; 65(5): 615-24.
6. Jordan GW, Statland B, Halsted C. CSF lactate in diseases of the CNS. *Arch Intern Med* **1983**; 143(1): 85-7.
7. Froman C, Smith AC. Metabolic acidosis of the cerebrospinal fluid associated with subarachnoid haemorrhage. *Lancet* **1967**; 1(7497): 965-7.
8. Maskin LP, Capparelli F, Mora A, et al. Cerebrospinal fluid lactate in post-neurosurgical bacterial meningitis diagnosis. *Clin Neurol Neurosurg* **2013**; 115(9): 1820-5.
9. Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. *The Lancet Infectious diseases* **2017**; 17(8): 873-81.
10. Ellis J, Bangdiwala AS, Cresswell FV, et al. The Changing Epidemiology of HIV-Associated Adult Meningitis, Uganda 2015-2017. *Open forum infectious diseases* **2019**; 6(10): ofz419.
11. Durski KN, Kuntz KM, Yasukawa K, Virnig BA, Meya DB, Boulware DR. Cost-effective diagnostic checklists for meningitis in resource-limited settings. *J Acquir Immune Defic Syndr* **2013**; 63(3): e101-8.
12. Rhein J, Huppler Hullsiek K, Tugume L, et al. Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial. *The Lancet infectious diseases* **2019**; 19(8): 843-51.
13. Cresswell FV, Tugume L, Bahr NC, et al. Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study. *The Lancet infectious diseases* **2020**; 20(3): 308-17.
14. Cresswell FV, Ellis J, Kagimu E, et al. Standardized Urine-Based Tuberculosis (TB) Screening With TB-Lipoarabinomannan and Xpert MTB/RIF Ultra in Ugandan Adults With Advanced Human Immunodeficiency Virus Disease and Suspected Meningitis. *Open forum infectious diseases* **2020**; 7(4): ofaa100.
15. Diehl JW, Hullsiek KH, Okirwoth M, et al. Cerebral Oximetry for Detecting High-mortality Risk Patients with Cryptococcal Meningitis. *Open Forum Infect Dis* **2018**; 5(6): ofy105.
16. Tugume L, Morawski BM, Abassi M, et al. Prognostic implications of baseline anaemia and changes in haemoglobin concentrations with amphotericin B therapy for cryptococcal meningitis. *HIV medicine* **2017**; 18(1): 13-20.
17. Jarvis JN, Bicanic T, Loyse A, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: implications for improving outcomes. *Clin Infect Dis* **2014**; 58(5): 736-45.
18. Bicanic T, Bottomley C, Loyse A, et al. Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. *Antimicrobial agents and chemotherapy* **2015**; 59(12): 7224-31.

## CSF Lactate In Cryptococcal Meningitis

19. Dienel GA, Rothman DL, Nordstrom CH. Microdialysate concentration changes do not provide sufficient information to evaluate metabolic effects of lactate supplementation in brain-injured patients. *J Cereb Blood Flow Metab* **2016**; 36(11): 1844-64.

## CSF Lactate In Cryptococcal Meningitis

**Table 1. Baseline Characteristics of Study Participants by CSF Lactate Tertile**

Characteristic	N with data	CSF Lactate Tertile			P-value
		Low $\leq 3.0$	Mid-Range 3.1 to 5.0	High $> 5.0$	
N	319	97	113	109	
CSF lactate, mmol/L	319	2.4 (2.1, 2.7)	3.8 (3.4, 4.4)	6.7 (5.6, 8.1)	
Men	319	51 (52.6%)	75 (66.4%)	79 (72.5%)	0.01
Age, years	319	34 (29, 40)	35 (30, 42)	38 (31, 45)	0.02
Glasgow Coma Score < 15	314	30 (31.3%)	39 (35.5%)	71 (65.7%)	<0.0001
Seizure	314	9 (9.4%)	17 (15.5%)	32 (29.6%)	0.0006
On HIV therapy	317	50 (52.1%)	51 (45.1%)	53 (49.1%)	0.60
Hemoglobin, g/dL	239	11 (10, 13)	12 (10, 14)	11 (9, 13)	0.29
CD4 cells/ $\mu$ L	225	14 (7, 38)	15 (6, 53)	25 (8, 58)	0.18
Creatinine, mg/dL	236	0.7 (0.6, 0.9)	0.7 (0.6, 0.9)	0.8 (0.6, 1.0)	0.28
CSF white cells/ $\mu$ L	313	4 (4, 20)	4 (4, 30)	4 (4, 130)	0.007
CSF Protein, mg/dL	270	50 (24, 102)	59 (29, 100)	65 (28, 122)	0.25
CSF Glucose, mg/dL	240	62 (42, 86)	59 (40, 72)	38 (22, 68)	0.0003
CSF Opening Pressures, cm H <sub>2</sub> O	280	22 (14, 30)	23 (16, 33)	27 (17, 40)	0.03
CSF culture, log <sub>10</sub> CFU/mL	306	4.0 (1.7, 5.3)	4.6 (2.5, 5.6)	4.6 (2.8, 5.4)	0.25
CSF removed, mL	290	10 (7, 16)	12 (9, 18)	12 (8, 19)	0.22
Blood Capillary Lactate, mmol/L	37	1.9 (1.9, 5.3)	2.9 (2.0, 4.5)	3.5 (1.8, 5.0)	0.72

Data are presented as median (IQR) or N (%).

P-value from Kruskal-Wallis test for medians, Chi-squared test for proportions

## CSF Lactate In Cryptococcal Meningitis

**Table 2: Hazard Ratios for 2-Week Mortality**

CSF Lactate (mmol/L)	Deaths N (%)	Hazard Ratio (95%CI)	P-value	Adjusted* Hazard Ratio (95%CI)	P-value
<b>By CSF Lactate Tertiles</b>					
≤3.0	9 (9%)	1.0		1.0	
3.1 to 5.0	25 (22%)	2.51 (1.17, 5.38)	0.02	1.99 (0.87, 4.52)	0.10
> 5.0	38 (35%)	4.21 (2.04, 8.71)	0.0001	3.41 (1.55, 7.51)	0.002
<b>By 1 mmol/L Increase in CSF Lactate</b>					
<b>1 unit increase</b>		1.16 (1.07, 1.27)	0.0005	1.13 (1.02, 1.24)	0.02
<b>By AUC Cut Off of CSF Lactate</b>					
<4.3	25 (14%)	1.0		1.0	
≥4.3	47 (33%)	2.53 (1.56, 4.12)	0.0002	2.10 (1.22, 3.62)	0.008

\*Adjusted for Glasgow Coma Score, baseline seizure, quantitative cryptococcal CSF culture, and CSF opening pressures

## CSF Lactate In Cryptococcal Meningitis


**Table 3: Baseline Characteristics of Patients with CSF Lactate >5.0 mmol/L, compared by 2-week survivor status**

Characteristic	Died by 2 weeks	Survived 2 weeks	P-value
<b>N</b>	38	71	
<b>Men</b>	25 (66%)	54 (76%)	0.22
<b>Age, years</b>	40 [33, 50]	37 [30, 42]	0.06
<b>Glasgow Coma Score &lt; 15</b>	29 (78%)	42 (59%)	<b>0.05</b>
<b>Seizure</b>	13 (35%)	19 (27%)	0.34
<b>On HIV therapy</b>	21 (55%)	32 (46%)	0.32
<b>Hemoglobin, g/dL</b>	10.2 [8.1, 12.6]	11.6 [9.7, 13.1]	<b>0.04</b>
<b>CD4 count, cells/<math>\mu</math>L</b>	20 [7, 52]	27 [10, 70]	0.33
<b>Creatinine, mg/dL</b>	0.8 [0.6, 1.7]	0.8 [0.6, 0.9]	<b>0.001</b>
<b>CSF Lactate, mmol/L</b>	7.0 [5.8, 7.7]	6.7 [5.5, 8.5]	0.57
<b>CSF White cells, per <math>\mu</math>L</b>	4.0 [4.0, 130.0]	4.5 [4.0, 130.0]	0.64
<b>CSF Glucose, mg/dL</b>	37.5 [20.0, 76.0]	39.0 [26.0, 61.0]	0.36
<b>CSF Opening Pressure, cm H<sub>2</sub>O</b>	27 [17, 43]	26 [18, 37]	0.22
<b>CSF culture, log<sub>10</sub>CFU/mL</b>	4.6 [2.6, 5.5]	4.6 [2.8, 5.4]	0.48
<b>CSF removed at baseline, mL</b>	13 [8, 20]	12 [8, 18]	0.63

Data are presented as median [IQR] or N (%)  
P-values from Cox proportional hazards models

## CSF Lactate In Cryptococcal Meningitis


**Figure 1: Distribution of Baseline CSF Lactate Measurements by 2-week survival**



Distribution of baseline CSF lactate among persons presenting with Cryptococcal meningitis. Persons presenting with a CSF lactate of  $>5.0$  mmol/L or greater were at a greater than 3 times the risk of mortality at 2 weeks ( $p<.0001$ ).


## CSF Lactate In Cryptococcal Meningitis

Figure 2: Mortality at 2-weeks by Baseline CSF Lactate Tertiles




## CSF Lactate In Cryptococcal Meningitis

**Figure 3: Relationship between CSF Lactate and Capillary Blood Lactate**



There was no correlation ( $R = 0.089$ ) between CSF lactate and capillary blood lactate at time of cryptococcal meningitis diagnosis ( $P = .72$ ).



CSF Lactate (mmol/L)

≤ 3.0	97	82	70
3.1–5.0	113	89	70
> 5.0	109	80	62